Asada, Shinji http://orcid.org/0000-0002-7717-8945
Yokoyama, Keitaro
Miyakoshi, Chisato
Fukuma, Shingo
Endo, Yuichi
Wada, Michihito
Nomura, Takanobu
Onishi, Yoshihiro
Fukagawa, Masafumi
Fukuhara, Shunichi
Akizawa, Tadao
Funding for this research was provided by:
Kyowa Kirin
Article History
Received: 4 August 2019
Accepted: 14 March 2020
First Online: 31 March 2020
Compliance with ethical standards
:
: SA, YE, TN, and MW are employees of Kyowa Kirin Co., Ltd. (KKC). KY has received consulting fees from Torii Pharmaceutical, and lecture fees from KKC, Torii Pharmaceutical, and Ono Pharmaceutical. CM and YO do not have any conflicts of interest to declare. S. Fukuma has acted as a scientific advisor for KKC. MF has received consulting fees from KKC and Ono Pharmaceutical; lecture fees from KKC, Bayer, Torii Pharmaceutical, and Ono Pharmaceutical; and grants from KKC and Bayer. S. Fukuhara has acted as a scientific advisor for and has received grants from KKC. TA has received consulting fees from KKC, Astellas Pharma, Bayer, Fuso Pharmaceutical, Japan Tobacco, Ono Pharmaceutical, Sanwa Chemical, Otsuka, GSK and NIPRO, and lecture fees from KKC, Chugai Pharmaceutical, Bayer, Kissei Pharmaceutical, Torii Pharmaceutical, and Ono Pharmaceutical.
: The study protocol was approved by the central ethics committee at Kobe University's School of Medicine (No. 754).
: Informed consent was not mandatory according to the ethical guidelines for epidemiological research in Japan. The study is registered at ClinicalTrials.gov (NCT00995163).